WuXi Advanced Therapies Competitors, Revenue, Alternatives and Pricing

Claim your profile


Total Funding:N/A
Lead Investor(s):N/A

Estimated Revenue & Financials

  • WuXi Advanced Therapies's estimated annual revenue is currently $67.7M per year.(?)
  • WuXi Advanced Therapies's estimated revenue per employee is $155,000

Employee Data

  • WuXi Advanced Therapies has 437 Employees.(?)
  • WuXi Advanced Therapies grew their employee count by 14% last year.
  • WuXi Advanced Therapies currently has 1 job openings.

Accelerating the Progress and Time to Market of Bio-Based Drugs through Integrated Manufacturing and Laboratory Testing Services Our Story By leveraging platforms and integrated testing, the Advanced Therapies business unit of WuXi AppTec is a streamlined Contract Development and Manufacturing Organization (CDMO), pioneering the expedited development and commercialization of cell, gene, protein and viral-based therapies. This approach enables new biopharmaceuticals to be developed, manufactured and released faster and with greater predictability, thereby reducing the complexities of high-touch, multi-vendor production models. Our solutions help clients overcome challenges to commercialization, including process development, manufacturing capacity, analytical development, and raw materials management. Multiple, scale-able, enabling platforms integrate manufacturing, process development and testing capabilities to provide greater predictability and speed to clinic. Well positioned for growth, our investments in personnel and manufacturing continue to expand clinical and commercial capacities. Since 2004, WuXi AppTec has supported Advanced Therapy programs with an extensive infrastructure of state-of-the-art, GMP-compliant facilities, providing centers of excellence for manufacturing and testing. Our Vision To significantly contribute to the growth of Advanced Therapies by accelerating and transforming development and manufacturing through our enabling platforms and technologies to the benefit of patients worldwide.